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Natural killer lytic-associatedmolecule (NKLAM) is an E3 ubiquitin ligase that plays a major
role in the cytolytic activity of NK cells. NKLAM is rapidly synthesized and then targeted
to the granule membranes of NK cells upon NK activation. Previous studies have shown
an essential role for NKLAM in NK killing activity in vitro. These findings were extended
to an in vivo model of NK-mediated tumor killing in which NKLAM-deficient knockout (KO)
mice injected with B16 melanoma cells were found to have significantly higher numbers
of pulmonary tumor nodules than wild-type (WT) mice. To further investigate the role of
NKLAM and NK function in tumor immunity in vivo, we utilized additional tumor models
to compare tumor development and progression in NKLAM KO and WT mice. Primary
tumor growth, dissemination, and metastasis of RMA-S lymphoma cells and E0771 breast
cancer cells were evaluated. Both tumor cell lines were stably transfected with constructs
that allow expression of green fluorescent protein (GFP), which serves as a tumor-specific
marker. Intravenous injection of NK-sensitive RMA-S lymphoma cells resulted in greater
dissemination of lymphoma cells in NKLAM KO mice than in WT mice. Lymphoma cells
were found in the lymph nodes and bone marrow (BM) of NKLAM KO mice 2 weeks
after injection; few detectable tumor cells remained in WT mice. E0771 syngeneic breast
cancer cells were injected into the mammary pads of NKLAM KO and WT mice. Primary
tumor growth was greater in NKLAM KO than in WT mice. More significantly, there were
4–5-fold more tumor cells in the blood and lungs of NKLAM KO than in WT mice 2 weeks
after injection of tumor cells into the mammary pad. These results indicate that NKLAM
plays a role in tumor development in vivo, especially in controlling tumor dissemination
and metastasis to distant sites.
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INTRODUCTION
Natural killer (NK) cells play an important role in defense against
tumors, viruses, and microbial pathogens. The anti-tumor and
anti-viral activities of NK cells are, in part, due to the direct
cytolytic activity of these cells (Herberman and Ortaldo, 1981;
Trinchieri, 1989; Lanier, 1998). NK cells are also potent pro-
ducers of various cytokines, including interferon (IFN)-γ and
tumor necrosis factor-α, which contribute to the role of NK
cells in inflammatory and immune responses (Kasahara et al.,
1983). NK cells can induce target cell death by a variety of
mechanisms. However, the primary mechanism of killing is the
release of cytotoxic granules containing perforin and granzymes
(Russell and Ley, 2002; Stinchcombe and Griffiths, 2007). It has
long been known that NK-mediated killing can be augmented
by cytokines, including IL-2, IL-12, IL-15, and IFN (Ortaldo
et al., 1980; Trinchieri et al., 1984; Kornbluth and Hoover, 1988;
Fehniger et al., 2007). In studies to characterize additional pro-
teins associated with the cytolytic process, we identified a novel
protein whose expression was highly increased upon cytokine
stimulation of NK cells (Kozlowski et al., 1999; Portis et al.,
2000). This protein was named NK lytic-associated molecule
(NKLAM).
NKLAM is an E3 ubiquitin ligase and a member of the
RING1-in between RING (IBR)-RING2 (RBR) family of pro-
teins (Fortier and Kornbluth, 2006). The N-terminus of NKLAM
contains the three cysteine-rich domains that comprise the RBR
structure and ubiquitin ligase activity (Fortier and Kornbluth,
2006). E3 ubiquitin ligases regulate the ubiquitination of proteins,
catalyzing the transfer of activated ubiquitin from an E2 ubiqui-
tin conjugating enzyme to its substrate (Pickart, 2001; Ardley and
Robinson, 2005). Although ubiquitination targets cellular pro-
teins for proteasomal degradation, it also regulates other cellular
functions, including lysosomal targeting, kinase and transcrip-
tion factor activation and DNA repair (Fang et al., 2003; Chen,
2005). Multiple E3 ubiquitin ligases have important roles in a
variety of immune functions, including receptor-mediated sig-
naling events and cytokine gene transcription (Rocca et al., 2001;
Anandasabapathy et al., 2003; Chuang and Ulevitch, 2004; Liu,
2004; Zhao et al., 2005; Nurieva et al., 2010). We have identified
NKLAM as an E3 ubiquitin ligase and are currently investigat-
ing how this enzymatic activity results in enhanced NK cytolytic
function (Fortier and Kornbluth, 2006). NKLAM also has at least
two predicted transmembrane domains, which is unique for E3
ubiquitin ligases (Kozlowski et al., 1999).
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Consistent with its predicted protein structure, NKLAM is
integrated into the cytolytic granule membranes of NK cells. It
is weakly expressed in resting NK cells and unlike perforin and
granzymes, there is little to no pre-formed NKLAM mRNA or
protein in NK cells. Upon target cell stimulation or after treat-
ment with cytokines that enhance NK killing, NKLAM mRNA
levels in NK cells increase; protein is synthesized and becomes
targeted to cytoplasmic granule membranes. As part of the
Immunological Genome Project, it was found that NKLAM is
transcriptionally up-regulated in Ly49H+ NK cells 1.5 days after
mouse cytomegalovirus infection (Bezman et al., 2012). Studies
have shown a role for NKLAM in perforin/granzyme-mediated
cytolysis. Treatment of NK cells with NKLAM antisense oligonu-
cleotides inhibits their killing activity, indicating that NKLAM
participates in the cytotoxic process (Kozlowski et al., 1999;
Portis et al., 2000). NK cells from NKLAM-deficient knockout
(KO) mice are significantly defective in lysing tumor target cells
(Hoover et al., 2009). In vivo, NKLAMKOmice also have reduced
NK activity. This is accompanied by higher numbers of lung
tumor colonies in NKLAMKO than in wild-type (WT)mice after
injection with B16 melanoma cells.
Many studies have documented the anti-tumor activity of
NK cells in vivo. NK cells have historically been found to be
most effective in recognizing and killing hematopoietic tumors.
However, there are studies linking higher levels of NK activ-
ity with better disease prognosis in patients with solid tumors
(Ishigami et al., 2000; Villegas et al., 2002). Conversely, there is an
epidemiological study showing that lowNK activity in the periph-
eral blood is associated with increased cancer risk (Imai et al.,
2000).
To further investigate the role of NKLAM in tumor immu-
nity, we examined the role of NK cells in preventing metasta-
sis using the NKLAM deficient mice as a model of defective
NK cells. We utilized two in vivo tumor models to compare
tumor development and progression in NKLAM KO and WT
mice. The first, RMA-S, a murine T cell lymphoma, is a well-
characterized NK-sensitive hematopoietic tumor (Karre et al.,
1986; Kim et al., 2000; Diefenbach et al., 2001). The second,
E0771, is a murine medullary breast carcinoma. This tumor
spontaneously arose from a C57BL/6 mouse (Sugiura and Stock,
1952). The E0771 cell line is poorly immunogenic, estrogen
receptor positive and highly prone to metastasis (Ewens et al.,
2005, 2006; Gu et al., 2009). Primary tumor growth, dissem-
ination, and metastasis of RMA-S lymphoma cells and E0771
breast cancer cells were evaluated. Results presented here indi-
cate that NKLAM plays a role in controlling tumor development
in vivo, especially tumor dissemination and metastasis to distant
sites.
MATERIALS ANDMETHODS
ANIMALS
The generation of mice deficient in NKLAM has been described
previously (Hoover et al., 2009). NKLAM KO and correspond-
ing C57BL/6 WT mice were housed in a pathogen-free facility.
Mice ranged in age from 3 to 5 months old. Studies were con-
ducted under protocols approved by the Saint Louis University
and St. Louis VA Animal Care and Use Committees.
CELL LINES
RMA-S T lymphoma cells (a gift from Todd Fehniger) were
cultured in RPMI 1640 media supplemented with 7.5% heat-
inactivated bovine growth serum (Hyclone), 1% L-glutamine,
and 1% penicillin–streptomycin. Cells were fed every other
day and maintained at a concentration of approximately
2 × 105 cells/mL. The C57BL/6-derived breast cancer cell line
E0771 was obtained from Dr. Rong Xiang (Scripps Research
Institute). Cells were split and fed twice a week in DMEM
supplemented with 15% bovine growth serum.
RMA-S and E0771 cells expressing green fluorescent pro-
tein (GFP) were generated for in vivo studies, in which GFP
serves as a tumor-specific marker. Cells were transfected with
a pcDNA3 vector (Invitrogen) containing the GFP gene cloned
from the pEGFP-N1 vector (Clontech). GFP-expressing RMA-S
cells (RMA-S-GFP) and E0771 cells (E0771-GFP) were selected
in media containing 800μg/mL and 1mg/mL G418, respectively.
GFP expression was verified by fluorescence microscopy, flow
cytometry, and PCR.
RMA-S-GFP AND INTRAVENOUS (TAIL VEIN) INJECTIONS
RMA-S-GFP cells (5 × 105) were injected into the tail vein of WT
and NKLAM KO mice. Four and twenty-four hours after intra-
venous injection of the cells, the mice were sacrificed and the liver,
lung, and blood were harvested. In some experiments, mice were
followed for 14 days after intravenous injection of tumor cells. In
addition to analysis of tumor survival in the lungs, dissemination
of tumor to the blood, bone marrow (BM), and lymph nodes was
assessed.
SUBCUTANEOUS INJECTIONS
RMA-S-GFP cells (5 × 105) were mixed 1:1 with Matrigel and
injected into the left flank of WT and NKLAM KO mice. E0771-
GFP cells (2 × 105) were mixed 1:1 with Matrigel and injected
into the mammary pads of syngeneic WT and NKLAM KO
mice. Primary tumor growth was measured twice a week using
calipers. Tumor volumes (mm3) were calculated using the for-
mula: (width)2 × length/2, where width is the smaller of the two
measurements. Mice were sacrificed at various days and primary
tumor, blood, liver, and lungs were harvested. Primary tumors
were dissected free of surrounding tissue, weighed and final
tumor volumes (mm3) calculated using the formula: width ×
length × depth/2. Pieces of tumor tissue, the right apical lobe
of the lung and sections of lymph node, spleen, and liver from
each animal were fixed in formalin and embedded in paraffin.
Sections were stained with hematoxylin and eosin (H&E) for his-
tological examination. Results were analyzed in a blinded fashion.
Lymph nodes, lung, and liver sections were also snap frozen in
liquid nitrogen and stored at −70◦C.
REAL TIME RT-PCR ANALYSES
These studies were performed as previously described (McHowat
et al., 2011). Briefly, the right azygous lobe of the lung and a
section of liver were snap frozen and the tissue was homog-
enized using a rotor-stator homogenizer (Tissuemiser, Fisher
Scientific). Blood was obtained by cardiac puncture. RNA was
prepared using the RNeasy Mini Kit (Qiagen) and cDNA using
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the TaqMan Reverse Transcription Gene Expression Assay kit
(Applied Biosystems). Real-time PCR analysis of GFP and 18 s
RNA was performed using GFP and 18 s RNA-specific Taqman
primer/probes and the ABI 7500 Real Time PCR System (Applied
Biosystems). GFP levels were analyzed as the change in Ct (Ct),
calculated with 18 s RNA as a housekeeping gene control. With
this technique, we can detect as few as 50 tumor cells in the
lungs and blood. We have shown previously that the quantita-
tive PCR measurements correlate with H&E histological analysis;
however, PCR can detect lower levels of metastasis than histology
(McHowat et al., 2011).
FLOW CYTOMETRY
Blood and BM were analyzed for the presence of tumor cells
by histology and flow cytometry. For isolation of BM, femurs
and tibias were dissected from euthanized mice. The bones were
flushed with DMEM to collect the marrow. BM cells were stained
with Wright–Giemsa stain.
RMA-S and E0771 cells were evaluated for cell surface
expression of MHC class I, CD45, CD62L and NKG2D lig-
ands (NKG2DL) by flow cytometry. Briefly, tubes containing
2 × 105 – 2 × 106 cells in 0.05mL of flow buffer (ice cold PBS +
1% FBS + 0.1% sodium azide) were incubated with 1 ul of Fc
block (BD Pharmingen) for 10min at 4◦C. Fluorescent conju-
gated cell surface-specific primary antibodies were then added
and incubated for an additional 30min at 4◦C. Cells were washed
twice with flow buffer and analyzed on a Becton Dickinson
FACScaliber flow cytometer. Antibodies PerCP CD45 and APC
CD62L were purchased from BD. PerCP-eFluor 710MHC class
I antibody was purchased from eBioscience. The NKG2D/CD314
Fc chimera was purchased from R&D Systems and PE-conjugated
F(ab’)2 goat anti-human Fc fragment specific IgG was from
Jackson ImmunoResearch. Flow cytometry was also performed
on blood for GFP expression. For analysis of total cell counts in
the blood, 10μL of unwashed blood was stained directly with
CD45 antibody and AccuCheck counting beads (Invitrogen) were
added just prior to flow analysis. Flow cytometric data were
analyzed with FlowJo software (Treestar).
STATISTICAL ANALYSIS
A two-tailed, unpaired Student’s t-test was used to compare the
means of two groups. A p-value of 0.05 or lower was considered
statistically significant.
RESULTS
ANALYSIS OF TUMOR CELL PERSISTENCE, DISSEMINATION, AND
METASTASIS
We developed a highly sensitive and quantitative PCR assay to
measure small numbers of tumor cells in vivo (McHowat et al.,
2011). Tumor cells are stably transfected with GFP cDNA, which
serves as a tumor-specific marker. Using a quantitative real time
PCR assay for detection of GFP, it is possible to identify tumor
cells in organs throughout the body that would otherwise be
undetectable.
CHARACTERIZATION OF TUMOR CELLS
The first set of experiments was performed using GFP-expressing
RMA-S tumor cells (RMA-S-GFP). RMA-S is a variant of the
Rauscher virus-induced C57BL/6 derived RBL-5 lymphoma,
defective for peptide loading of MHC class I molecules. Due to
its lack of stable cell surface MHC class I expression, RMA-S is
an NK-sensitive target in vitro and in vivo (Karre et al., 1986;
Kim et al., 2000; Diefenbach et al., 2001). As previously reported
and shown here, RMA-S also lacks expression of NKG2D lig-
ands (NKG2DL) (Cerwenka et al., 2001). It does, however, express
L-selectin (CD62L), which is critical for entry of cells into lymph
nodes (Figure 1).
FIGURE 1 | Flow cytometric analysis of RMA-S and E0771 tumor
cells. RMA-S and E0771 cells were immunostained for cell surface
expression of MHC class I, NKG2D ligands (NKG2DL), and L-selectin
(CD62L). Histograms depict RMA-S in blue and E0771 in red.
The X axes indicate the fluorescence intensity of staining for
MHC class I, NKG2DL, and CD62L. The Y axes represent the
number of cells analyzed, normalized to the percentage of maximum
events.
www.frontiersin.org December 2012 | Volume 3 | Article 393 | 3
Hoover et al. NKLAM controls tumor metastasis
The murine medullary breast carcinoma line E0771 spon-
taneously arose from a C57BL/6 mouse (Sugiura and Stock,
1952). This cell line is poorly immunogenic, estrogen recep-
tor positive and highly metastatic (Ewens et al., 2005, 2006;
Gu et al., 2009). As shown in Figure 1, E0771 expresses MHC
class I and NKG2D ligands but lacks cell surface expression
of CD62L.
NKLAM PLAYS A ROLE IN LYMPHOMA SURVIVAL AND
DISSEMINATION
NKLAM KO and WT mice were injected with RMAS-GFP lym-
phoma cells intravenously. Four hours later, tumor survival in the
lungs was assessed by quantitative PCR, in which GFP PCR lev-
els in the lungs represent the number of tumor cells surviving.
Results of five independent experiments as well as the compilation
of the five experiments are shown in Figures 2A,B, respectively.
We found that 2.8 times more RMAS-GFP tumor cells survived
in the lungs of NKLAM KO mice compared to WT mice 4 h
after intravenous injection (p < 0.02). This represents an 11-fold
decrease in tumor burden in NKLAM KO mice compared to a
30-fold decrease in WT mice.
We also examined the blood of these mice 4 h after injec-
tion of tumor cells for the presence of circulating GFP+ RMA-S
cells by flow cytometry. CD45 was used to gate the total leuko-
cyte population in the blood, inclusive of RMA-S. There were
very few, but detectable, tumor cells in the circulation. WT mice
had an average of 349 GFP+ cells within the CD45+ popula-
tion per μL of blood while NKLAM KO mice had an average of
1100 GFP+ cells, representing over 3-fold (3.2) more tumor cells
than WT (p < 0.02) (Figure 3A). Representative flow analyses
are shown in Figure 3B. By quantitative real-time PCR analy-
sis of GFP levels in the blood, a similar (2.9-fold) difference in
tumor levels between NKLAM KO and WT mice was observed
(p < 0.04). These results indicate that NKLAM KO mice are less
capable than WT mice of eliminating RMA-S tumor cells from
the lungs and the circulation.
The elimination of RMA-S cells in vivo is extremely rapid. Over
90% of the cells that reach the lung after intravenous (tail vein)
injection are killed within 4 h in WT mice. To evaluate the persis-
tence of tumor cells beyond this early time point, we utilized PCR
to identify RMA-S-GFP cells in the lungs and blood of mice 24 h
after intravenous injection. We were able to detect a low GFP sig-
nal in the lungs of both NKLAMKO andWTmice by PCR. Again,
NKLAMKOmice had 2.5-foldmore RMA-S cells persisting in the
lungs than WT mice 24 h after injection (p < 0.05) (Figure 4).
Since we were able to detect a small number of RMA-S tumor
cells persisting in the lungs of mice 24 h after intravenous injec-
tion, we next evaluated whether any of these cells ultimately
disseminated to lymphoid or other organs. Accordingly, we exam-
ined a series of NKLAM KO and WT mice 14 days after intra-
venous injection of RMA-S-GFP cells. At 14 days, we were unable
to detect any RMA-S lymphoma cells in the lungs by PCR. Lung
weights were equivalent between NKLAM KO and WT mice.
The lymph nodes were examined for evidence of lymphoma dis-
semination. Of great significance was the finding that 88% of
NKLAM KO mice had tumor cells in their lymph nodes, while
less than 25% of WT mice were lymph node positive. BM from
FIGURE 2 | Greater persistence of RMA-S-GFP cells in the lungs of
NKLAM KO than WT mice. Four hours after intravenous injection of
RMA-S-GFP cells, lungs from NKLAM KO and WT mice were analyzed for
GFP expression by quantitative PCR. (A) Depicts the results of five
independent experiments. Experiment 1: WT mice n = 3, NKLAM KO mice
n = 3; Experiment 2: WT n = 6, NKLAM KO n = 6; Experiment 3: WT
n = 6, NKLAM KO n = 4; Experiment 4: WT n = 4, NKLAM KO n = 4;
Experiment 5: WT n = 5, NKLAM KO n = 6. (B) Depicts the compilation of
the five experiments (WT mice n = 24, NKLAM KO mice n = 23) (p < 0.02).
NKLAM KO and WT mice was also examined for the pres-
ence of tumor cells. BM smears were made and scored blind
by a hematopathologist. Differential counts were performed to
quantitate the number of tumor cells in each WT and KO BM
sample. BM from six WT and eight NKLAMKOmice were evalu-
ated. The average percentage of RMA-S lymphoma cells in the BM
of WT mice was 0.8% (range 0.17–1.5%); the average in NKLAM
KO mice was 20.9% (range 16.5–26%). This represents a 26-fold
difference in tumor burden (p < 0.001). Two examples are shown
in Figure 5.
In the next series of experiments, RMA-S-GFP cells were
injected subcutaneously into NKLAM KO and WT mice in order
to compare primary tumor growth rates. At sacrifice on day
20, we found no significant difference in primary tumor weight
between NKLAM KO and WT mice. However, 80% of NKLAM
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FIGURE 3 | Higher levels of circulating RMA-S-GFP cells in the blood of
NKLAM KO than WT mice. Four hours after intravenous injection of
RMA-S-GFP cells, blood from NKLAM KO (n = 5) and WT mice (n = 5)
were analyzed for GFP expression by flow cytometry. (A) Results are
expressed as the number of GFP+ CD45+ cells per μL of blood.
(p < 0.02). (B) Representative histogram plots of blood from NKLAM KO
and WT blood are shown. Tumor cells (GFP+ CD45+) are within the box.
The percentage of GFP+ RMA-S cells within the CD45+ population in each
sample is shown.
KO mice had evidence of tumor in their lymph nodes while
only 27% of WT mice were lymph node positive (p = 0.0001)
(Table 1). Positive lymph nodes recovered fromWT and KOmice
on day 20 were completely replaced by RMA-S lymphoma cells.
Representative histology of a tumor-positive lymph node from a
KO mouse is shown in Figure 6. Nests and sheets of lymphoma
cells are seen, the lymph node architecture is effaced, and lym-
phoma cells have extended through the lymph node capsule into
the perinodal adipose tissue. Lymph nodes recovered from WT
mice showed similar histology. Cumulatively, these results suggest
that NKLAM KO mice are less capable of controlling lymphoma
dissemination than WT mice.
FIGURE 4 | Persistence of RMA-S-GFP cells in the lungs of NKLAM KO
mice 24 h after intravenous injection. Lungs from tumor-injected NKLAM
KO (n = 4) and WT mice (n = 4) were analyzed for GFP expression by
quantitative PCR (p < 0.05).
FIGURE 5 | Greater numbers of RMA-S-GFP cells disseminate to the
bone marrow (BM) of NKLAM KO than WT mice 14 days after
intravenous injection. BM from NKLAM KO (n = 6) and WT mice (n = 8)
was harvested 14 days after tumor injection and stained with Wright
Giemsa stain. Arrows indicate the RMA-S tumor cells. Based upon standard
differential counts, there were 26-fold more tumor cells present in the BM
of NKLAM KO mice than WT mice (p < 0.001).
Table 1 | Primary tumor weight and lymph node dissemination of
RMA-S tumors 21 days after subcutaneous injection.
Tumor weight (g) Frequency of tumor
in lymph nodes
WT 2.6 ± 0.21 (n = 18) 3/11
NKLAM KO 2.4 ± 0.21 (n = 21) 12/15*
Data represent means ± SE; *p < 0.0001.
NKLAM PLAYS A ROLE IN CONTROL OF BREAST CANCER METASTASIS
To examine the potential role of NKLAM in controlling breast
cancer growth and metastasis, mammary pads of WT and
NKLAM KO female mice were injected with 200,000 GFP-
expressing E0771 cells. Mice were observed for up to 29 days
and primary tumor volume (mm3) measured at regular inter-
vals (Figure 7). Tumor growth was slightly higher in NKLAM
KO than in WT mice. The tumor weights at sacrifice were also
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FIGURE 6 | Histological examination of RMA-S tumors. Sections of
lymph nodes from mice 20 days after subcutaneous injection of RMA-S
were stained with H&E. A section of tumor-involved lymph node from an
NKLAM KO mouse at 40× and 400× magnification is shown. At 40×, it is
evident that the normal lymph node architecture is completely effaced and
tumor cells have extended through the capsule into the perinodal adipose
tissue. Histological examination at 400× reveals extensive replacement of
the node by large, anaplastic RMA-S tumors cells and many apoptotic cells.
These findings are indicative of replacement of the lymph node by a rapidly
proliferating lymphoma.
FIGURE 7 | Growth of E0771 primary tumors in NKLAM KO and WT
mice. GFP-expressing E0771 cells were injected into the mammary pads of
female mice. Mice were observed for up to 29 days and primary tumors
were measured at regular intervals with calipers (NKLAM KO mice, n = 21;
WT mice, n = 18). Tumor volume is expressed as mm3 (∗p ≤ 0.04).
somewhat higher in NKLAM KO mice, but the differences were
not statistically significant.
E0771 breast cancer cells often metastasize to distant sites. To
compare levels of metastasis in NKLAMKO andWTmice, a series
of mice were sacrificed 24 days after tumor initiation. Primary
tumor, blood, liver, and lungs were harvested. Lungs, liver, and
blood were analyzed for tumormetastasis by quantitative RT-PCR
analysis of GFP, which can identify metastasis that would other-
wise be undetectable by other methodologies. We were unable to
detect tumor cells in the liver of these mice. However, there was
significant GFP expression, reflecting tumor cells, in the blood
FIGURE 8 | Higher levels of metastasis of E0771 in NKLAM KO than WT
mice. (A) Lungs and (B) blood were collected from mice 24 days after
primary breast tumor growth. Tumor metastasis and dissemination were
evaluated by quantitative PCR for GFP expression. WT mice, n = 5; NKLAM
KO mice, n = 6 (A, p < 0.05; B, p = 0.02).
and lungs of all mice. NKLAM KO mice had over four times
more E0771 cells in the lungs and over five times more E0771
cells in the blood than WT mice (Figure 8). These differences
were highly significant (p ≤ 0.02). Figure 9 represents histolog-
ical analysis of a lung from an NKLAM KO mouse with a high
level of metastasis, as determined by PCR analysis of GFP levels.
A focus of E0771 tumor cells is clearly identifiable in this sec-
tion of lung. However, overall, the level of tumor metastasis to
the lung in mice at this time point was too low to detect histo-
logically in the majority of animals. Real-time quantitative PCR
analysis of GFP levels in the blood and lung allowed for the detec-
tion of micro-metastases which were undetectable by histology.
Therefore, although primary breast cancer tumor growth is only
slightly higher in NKLAM KO mice compared to WT, NKLAM
KO mice have significantly higher levels of lung metastasis and
more tumor cells disseminated through the bloodstream than
WT mice.
DISCUSSION
Studies were performed to further investigate the role of NKLAM
in tumor immunity. NKLAM-deficient mice have defective NK
function and therefore act as a model to evaluate the role of NK
cells in tumor metastasis and dissemination. Two in vivo tumor
models were utilized to compare both tumor development and
its progression in NKLAM KO and WT mice. One is the RMA-S
T cell lymphoma model. RMA-S is a well-described NK-sensitive
target in vitro and in vivo. Intravenous injection of NK-sensitive
RMA-S lymphoma cells through the tail vein resulted in greater
persistence of tumor cells in the lungs of NKLAM KO mice com-
pared to WT mice. NKLAM KO mice also had higher levels of
tumor cells in the circulation. Over time, lymphoma cells dissem-
inated to the lymph nodes and BM of NKLAM KO mice while
few to no tumor cells were detectable in WT mice. These results
suggest that NKLAM KO mice are less capable of killing RMA-S
tumor cells in vivo, thereby allowing surviving tumor cells to
disseminate to distant sites.
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FIGURE 9 | Histological analysis of a lung from an NKLAM KO mouse
24 days after mammary pad injection of E0771. Lungs were collected
from mice 24 days after primary tumor growth and sections stained with
H&E. A focus of E0771 cells in the lung of a mouse with a high level of
metastasis is depicted. The surrounding, uninvolved lung tissue shows
atelectasis and infiltration by acute and chronic inflammatory cells (primarily
mature granulocytes and small lymphocytes and monocytes).
The potential role of NKLAM in the process of lymphoma dis-
semination was further examined by injecting RMA-S-GFP cells
into mice subcutaneously. Studies have shown that low num-
bers of RMA-S cells are rejected by immunocompetent mice. At
high doses (105 and above), tumors develop in nearly 100% of
mice (Screpanti et al., 2001). In the studies presented here, mice
were injected with a dose of tumor cells that generates tumors
in all mice. Primary tumor growth rate and tumor weights were
equivalent in NKLAMKO andWTmice. However, dissemination
of lymphoma to the lymph nodes was observed in the majority
(80%) of NKLAM KO mice, while only 27% of WT mice were
lymph node positive. These results additionally support a role for
NKLAM in lymphoma dissemination in vivo.
Breast cancer growth and metastasis was the second tumor
model used to evaluate the potential role of NKLAM in tumor
immunity. Breast cancer is the second leading cause of death from
cancer in women. Metastatic breast cancer, at time of diagnosis,
is a negative prognostic indicator, and distant site metastasis is
a major cause of death in cancer patients. For these studies, we
injected female mice with syngeneic E0771 breast cancer cells.
E0771 tumors are estrogen receptor positive, poorly immuno-
genic, aggressive, and metastatic, with characteristics that closely
mirror those of the human disease. They are also CD73 pos-
itive, which is associated with a pro-metastatic phenotype in
breast cancer and escape from anti-tumor immunity (Stagg et al.,
2010). Mammary pad injection of E0771 tumor cells results in
tumor formation in almost 100% of mice. By histological analy-
sis, it has been reported that secondary tumors form in the lungs
of 52% of mice (Ewens et al., 2005). However, this is likely a
conservative estimate. By PCR analysis, we detect some level of
metastasis to the lung in nearly all mice. Human breast cancer
often metastasizes to the lungs, suggesting that E0771 may be a
better model of human disease than other subcutaneously grown
tumors.
Primary tumor growth and metastasis of E0771 breast cancer
cells was evaluated. Primary tumor growth was slightly greater in
NKLAM KO than in WT mice. The dose of E0771 cells injected
into the mammary pads of mice in these experiments is high,
resulting in tumors in 100% of mice. It is possible that differences
in primary tumor growth between NKLAM KO and WT mice
would bemore apparent by injecting fewer tumor cells. To address
this, limiting dilution analyses are now in progress. Of great inter-
est is the finding of significant differences in tumor metastasis
between NKLAM KO and WT mice. There were 4–5-fold more
tumor cells in the blood and lungs of NKLAM KO than in WT
mice 2 weeks after injection of tumor cells into themammary pad.
The pathogenesis of metastasis is complex, requiring a series
of events, including synthesis and secretion of angiogenic fac-
tors to promote neovascularization, motility, local invasion of the
stroma, extravasation and entry into the circulation. Our work-
ing hypothesis is that NKLAM, through its role in NK-mediated
cytotoxicity, influences the ability of tumor cells to survive in the
circulation, thereby limiting tumor dissemination and metastasis.
This would establish NK anti-tumor activity as a mechanism for
controlling the process of tumor spread. Others have presented
data consistent with a role for NK cells in controlling metas-
tasis. Using a murine breast cancer model, Tkach et al. found
that immunization of Balb/c mice with tumor cells expressing
dominant-negative Stat3 decreased the level of tumor metastasis.
They demonstrated that depletion of NK cells abrogated the anti-
tumor effect of immunization and that vaccination increased the
number of tumor-infiltrating NK cells (Tkach et al., 2012). The
metastasis-associated microRNA miR-10b was found to down-
regulate MICB, thereby impairing the ability of tumor cells to
be eliminated by NK killing. Conversely, using an in vivo model
of lung metastasis, more tumor cells overexpressing miR-10b
were present in the lungs compared with control tumor cells
(Tsukerman et al., 2012). These studies demonstrate a link
between NK cytotoxicity and control of metastasis. Our results
are consistent with this hypothesis for the following reasons. In
the first tumor model, RMA-S is a well-characterized NK sensi-
tive target. Due to its lack of cell surface MHC class I expression,
little to no cytotoxic T cell (CTL) activity is generated against
these cells (Cerwenka et al., 2001; Zompi et al., 2003). The differ-
ences between NKLAM KO and WT mice in control of RMA-S
in vivo are seen within 24 h, long before adaptive immunity
would be generated. The finding that dissemination of these lym-
phoma cells to the BM and lymph nodes is seen predominantly in
NKLAM KO mice is consistent with the hypothesis that NKLAM
KO NK cells are less capable of killing RMA-S tumor cells in vivo,
thereby allowing surviving tumor cells to disseminate to distant
sites. In the second tumor model, E0771 breast cancer cells are
poorly immunogenic and incapable of generating primary CTL
responses in vivo (Ewens et al., 2005, 2006; Zhou et al., 2005).
Their expression of CD73 contributes to their inability to gener-
ate adaptive anti-tumor immunity (Stagg et al., 2010). However,
we have shown that these cells express high levels of NKG2D lig-
ands, which allows them to be potential NK targets. Our results
suggest that NK cells may be relatively ineffective in controlling
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primary breast tumor growth in the mammary pad, particularly
given the large number of tumor cells that were injected in these
studies. However, NK cells may be able to identify and kill the
small numbers of tumor cells that escape from the mammary pad
into the circulation, thereby reducing the incidence of metastasis.
NKLAM KO NK cells are also defective in IFN-γ production, so
it is possible that IFN may also contribute to these effects.
Cancer is the second most prevalent cause of death, and the
majority of cancer deaths are caused by distant metastases rather
than by growth of the primary tumor (Heyder et al., 2005).
Development of new management strategies that target metas-
tasis development will improve cancer morbidity and mortality
outcomes. Further delineation of the precise mechanism by
which NKLAM functions to prevent tumor dissemination and
metastasis is currently under investigation.
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